What is the confirmed market size and growth trajectory for the global cold chain logistics market?
The market was valued at USD 415.6 billion in 2025 and is projected to grow at a CAGR of 7.0% to USD 764.06 billion by 2035. Transportation holds the dominant service type revenue share. Refrigerated warehousing is the dominant warehousing type. Pharmaceuticals and biologics is the fastest-growing application. Active cold chain is the dominant temperature control method. The chilled 2°C to 8°C temperature range is the largest by revenue. North America leads by revenue; Asia-Pacific is fastest-growing.

What makes pharmaceuticals and biologics the fastest-growing cold chain application?
Biologics — protein-based drugs including monoclonal antibodies, vaccines, insulin, and recombinant proteins — require 2°C to 8°C continuous cold chain integrity from manufacturing to patient administration. Cell and gene therapies additionally require ultra-low temperatures below -70°C and in many cases cryogenic storage below -150°C — creating the most technically demanding and highest-value cold chain requirements in any product category. As biologics and cell therapies grow from approximately 40% to a projected 55% of the global pharmaceutical pipeline by 2030, each percentage point of biologics market share growth creates proportionately larger cold chain logistics demand.

How does IoT-enabled temperature monitoring transform cold chain risk management?
IoT temperature data loggers, real-time GPS telematics, and cloud-based visibility platforms enable cold chain operators to monitor shipment temperature, location, and condition continuously from origin to destination — with automated alerts triggering corrective action when temperature excursions are detected before product quality is compromised. This real-time monitoring capability is shifting cold chain risk management from retrospective documentation — where excursions are discovered upon delivery — to proactive intervention that protects product integrity during transit. Regulatory agencies including FDA and EMA are progressively requiring real-time temperature monitoring documentation for pharmaceutical cold chain shipments.

How is fresh grocery e-commerce creating structural last-mile cold chain investment demand?
Fresh grocery e-commerce — where consumers order produce, meat, dairy, and meal kits for home delivery — requires refrigerated last-mile delivery infrastructure that conventional grocery logistics cannot provide. Each grocery delivery vehicle must maintain chilled 2°C to 8°C and frozen -18°C zones simultaneously, while completing 20 to 40 consumer deliveries per route at commercially viable per-order delivery cost. This last-mile cold chain requirement is driving investment in electric refrigerated delivery vehicles, insulated delivery packaging that maintains temperature for 2 to 8 hours post-vehicle delivery, and micro-fulfilment dark store networks positioned within 30-minute delivery range of consumer density.

What is driving warehouse automation adoption in cold storage facilities above ambient warehouse automation rates?
Cold storage warehouse automation — AS/RS systems, AGVs, and robotic picking operating in sub-zero environments — is being adopted at rates above ambient warehouse automation because the labour availability crisis is most acute in cold storage environments where workers are limited by regulatory working time restrictions in freezing temperatures. Automated systems can operate continuously in -25°C frozen storage and -70°C deep-frozen environments without the labour exposure limitations that restrict human working hours — creating an even stronger economic case for automation in cold storage than in ambient warehousing.

How do government and NGO cold chain programmes for vaccine distribution create structured public-sector demand?
WHO’s Expanded Programme on Immunization, COVAX vaccine delivery infrastructure, and national government public health immunisation programmes create structured public-sector cold chain procurement that is independent of commercial market demand cycles. Vaccine cold chain logistics — requiring 2°C to 8°C integrity from manufacturer to last-mile health clinic in remote rural settings — drives cold chain investment in developing markets where commercial pharmaceutical logistics infrastructure is insufficient.